Kanthariplus Suraksha Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 1.00 M
as on 24-10-2024
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.90 M
as on 24-10-2024
- Revenue %
(FY 2023)
- Profit 1064.61%
(FY 2023)
- Ebitda 564.61%
(FY 2023)
- Net Worth 4.90%
(FY 2023)
- Total Assets 321.64%
(FY 2023)
About Kanthariplus Suraksha Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹4.90 M.
Krishnamallan Gopinathamallan, Vijayakumari, and Balakrishnan Murali serve as directors at the Company.
- CIN/LLPIN
U24290KL2019PTC060592
- Company No.
060592
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2019
- Date of AGM
31 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Alappuzha, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kanthariplus Suraksha Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishnamallan Gopinathamallan  | Director | 10-Jul-2023 | Current |
| Vijayakumari | Director | 10-Jul-2023 | Current |
| Balakrishnan Murali | Director | 10-Jul-2023 | Current |
Financial Performance of Kanthariplus Suraksha Pharma.
Kanthariplus Suraksha Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 1064.61% increase in profit. The company's net worth moved up by a moderate rise of 4.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kanthariplus Suraksha Pharma?
In 2023, Kanthariplus Suraksha Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shenoi's Farms LimitedActive 9 years 9 monthsKrishnamallan Gopinathamallan and . Vijayakumari are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Mar 2024 | ₹4.90 M | Open |
How Many Employees Work at Kanthariplus Suraksha Pharma?
Unlock and access historical data on people associated with Kanthariplus Suraksha Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kanthariplus Suraksha Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kanthariplus Suraksha Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
